INVESTIGADORES
MALCHIODI Emilio Luis
artículos
Título:
Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model.
Autor/es:
CAZORLA SI, FRANK FM, BECKER P, CORRAL RS, GUZMAN CA, MALCHIODI EL.
Revista:
VACCINE
Editorial:
ELSEVIER SCI LTD
Referencias:
Año: 2008 vol. 26 p. 1999 - 2009
ISSN:
0264-410X
Resumen:
Cruzipain (Cz), a key Trypanosoma cruzi enzyme, is a main candidate antigen for vaccines against ChagasÂ’ disease. We evaluated a vaccination protocol based on intradermal priming with recombinant Cz and intranasal boosting with rCz co-administered with a derivative of the TLR2/6 agonist MALP-2. Vaccination triggered strong systemic and mucosal antibody responses, and a vigorous cell-mediated immunity characterized by lymphoproliferation, DTH reactivity and IFN-g production. The immune responses protected against a lethal trypomastigote challenge and, upon sub-lethal infection, immunized mice showed reduction of tissue damage and normal enzymatic markers of muscle injury. This prime-boost regimen appears promising for further development, since warranted survival, provided efficient control of parasite load and restricted inflammatory myopathy.